CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP) Apr 07, 2021 4:01pm EDT
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications Apr 07, 2021 6:00am EDT
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory Apr 05, 2021 6:05am EDT
First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later Apr 05, 2021 6:00am EDT
CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its Activities Apr 01, 2021 6:15am EDT
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial With 2 Doses Apr 01, 2021 6:00am EDT
CytoDyn’s Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients Mar 30, 2021 6:00am EDT
Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of Translational Autoimmunity Mar 29, 2021 6:15am EDT
